Table 1.
Baseline characteristics of patients who have received surgery and multidisciplinary treatment discussion (N=4475).
| Characteristics | Values, n (%) | P value | ||||||
|
|
Total (n=4475) | Pre-App cohort (n=2966) | App nonused cohort (n=861) | App used cohort (n=648) |
|
|||
| Age (years) | <.001 | |||||||
|
|
≤50 | 1662 (37.1) | 1100 (37.1) | 293 (34) | 269 (41.5) |
|
||
|
|
50-70 | 2304 (51.5) | 1535 (51.8) | 435 (50.5) | 334 (51.5) |
|
||
|
|
>70 | 509 (11.4) | 331 (11.2) | 133 (15.4) | 45 (6.9) |
|
||
| Educational levela | .70 | |||||||
|
|
Middle school or lower | 1673 (38.2) | 1104 (38.1) | 334 (39.2) | 235 (37.1) |
|
||
|
|
High school or higher | 2709 (61.8) | 1792 (61.9) | 518 (60.8) | 399 (62.9) |
|
||
| Marital status | .14 | |||||||
|
|
Married | 4315 (96.4) | 2857 (96.3) | 825 (95.8) | 633 (97.7) |
|
||
|
|
Others | 160 (3.6) | 109 (3.7) | 36 (4.2) | 15 (2.3) |
|
||
| Menopausal status | .002 | |||||||
|
|
Pre | 1728 (38.6) | 1144 (38.6) | 300 (34.8) | 284 (43.8) |
|
||
|
|
Post | 2747 (61.4) | 1822 (61.4) | 561 (65.2) | 364 (56.2) |
|
||
| Benign breast disease history | <.001 | |||||||
|
|
Yes | 967 (21.6) | 572 (19.3) | 228 (26.5) | 167 (25.8) |
|
||
|
|
No | 3508 (78.4) | 2394 (80.7) | 633 (73.5) | 481 (74.2) |
|
||
| Malignant disease history | <.001 | |||||||
|
|
Yes | 209 (4.7) | 111 (3.7) | 56 (6.5) | 42 (6.5) |
|
||
|
|
No | 4266 (95.3) | 2855 (96.3) | 805 (93.5) | 606 (93.5) |
|
||
| Family history of breast cancer | .002 | |||||||
|
|
Yes | 340 (7.6) | 197 (6.6) | 86 (10) | 57 (8.8) |
|
||
|
|
No | 4135 (92.4) | 2769 (93.4) | 775 (90) | 591 (91.2) |
|
||
| Comorbidity | .01 | |||||||
|
|
Yes | 1766 (39.5) | 1184 (39.9) | 359 (41.7) | 223 (34.4) |
|
||
|
|
No | 2709 (60.5) | 1782 (60.1) | 502 (58.3) | 425 (65.6) |
|
||
| Breast surgery | <.001 | |||||||
|
|
Breast conserving | 1597 (35.7) | 1004 (33.9) | 357 (41.5) | 236 (36.4) |
|
||
|
|
Mastectomy | 2878 (64.3) | 1962 (66.1) | 504 (58.5) | 412 (63.6) |
|
||
| Axillary surgeryb | <.001 | |||||||
|
|
SLNBc | 2940 (66.2) | 1905 (64.6) | 626 (74) | 409 (63.2) |
|
||
|
|
ALNDd | 1501 (33.8) | 1043 (35.4) | 220 (26) | 238 (36.8) |
|
||
| Tumor sizee | .40 | |||||||
|
|
≤2 cm | 2542 (58) | 1669 (58) | 511 (59.3) | 362 (55.9) |
|
||
|
|
>2 cm | 1843 (42) | 1207 (42) | 350 (40.7) | 286 (44.1) |
|
||
| Lymph node statusf | <.001 | |||||||
|
|
Negative | 2905 (65.4) | 1943 (65.9) | 605 (71.5) | 357 (55.3) |
|
||
|
|
Positive | 1535 (34.6) | 1005 (34.1) | 241 (28.5) | 289 (44.7) |
|
||
| Pathological subtype | <.001 | |||||||
|
|
IDCg | 3848 (86) | 2578 (86.9) | 690 (80.1) | 580 (89.5) |
|
||
|
|
Non-IDC | 627 (14) | 388 (13.1) | 171 (19.9) | 68 (10.5) |
|
||
| Tumor grade | <.001 | |||||||
|
|
I or II | 2253 (50.3) | 1437 (48.4) | 469 (54.5) | 347 (53.5) |
|
||
|
|
III | 1574 (35.2) | 1137 (38.3) | 212 (24.6) | 225 (34.7) |
|
||
|
|
Unknown | 648 (14.5) | 392 (13.2) | 180 (20.9) | 76 (11.7) |
|
||
| LVIh | <.001 | |||||||
|
|
No | 3926 (87.7) | 2689 (90.7) | 722 (83.9) | 515 (79.5) |
|
||
|
|
Yes | 549 (12.3) | 277 (9.3) | 139 (16.1) | 133 (20.5) |
|
||
| Estrogen receptor status | .01 | |||||||
|
|
Negative | 160 (24.7) | 780 (26.3) | 184 (21.4) | 160 (24.7) |
|
||
|
|
Positive | 3351 (74.9) | 2186 (73.7) | 677 (78.6) | 488 (75.3) |
|
||
| Progesterone receptor status | <.001 | |||||||
|
|
Negative | 1629 (36.4) | 1153 (38.9) | 254 (29.5) | 222 (34.3) |
|
||
|
|
Positive | 2846 (63.6) | 1813 (61.1) | 607 (70.5) | 426 (65.7) |
|
||
| HER2i status | .001 | |||||||
|
|
Negative | 3435 (76.8) | 2280 (76.9) | 689 (80) | 466 (71.9) |
|
||
|
|
Positive | 1040 (23.2) | 686 (23.1) | 172 (20) | 182 (28.1) |
|
||
| Ki-67 | <.001 | |||||||
|
|
<14% | 1400 (31.3) | 1029 (34.7) | 245 (28.5) | 126 (19.4) |
|
||
|
|
≥14% | 3075 (68.7) | 1937 (65.3) | 616 (71.5) | 522 (80.6) |
|
||
| Molecular subtype | <.001 | |||||||
|
|
Luminal-A like | 923 (20.6) | 657 (22.2) | 184 (21.4) | 82 (12.7) |
|
||
|
|
Luminal-B like (HER2-negative) | 1903 (42.5) | 1206 (40.7) | 399 (46.3) | 298 (46) |
|
||
|
|
Luminal-B like (HER2-positive) | 540 (12.1) | 331 (11.2) | 97 (11.3) | 112 (10.8) |
|
||
|
|
HER2 positive | 500 (11.2) | 355 (12) | 75 (8.7) | 70 (10.8) |
|
||
|
|
Triple negative | 609 (13.6) | 417 (14.1) | 106 (12.3) | 86 (13.3) |
|
||
| TNMj stagek | .003 | |||||||
|
|
Stage I | 1954 (44.7) | 1289 (44.8) | 415 (49.1) | 250 (38.7) |
|
||
|
|
Stage II | 1839 (42.1) | 1213 (42.1) | 329 (38.9) | 297 (46) |
|
||
|
|
Stage III | 577 (13.2) | 376 (13.1) | 102 (12.1) | 99 (15.3) |
|
||
aA total of 993 patients had missing data of educational level.
bA total of 34 patients had missing data of axillary surgery procedure.
cSLNB: sentinel lymph node biopsy.
dALND: axillary lymph node dissection.
eA total of 90 patients had missing data of tumor size.
fA total of 35 patients had missing data of lymph node status.
gIDC: invasive ductal carcinoma.
hLVI: lymphovascular invasion.
iHER2: human epidermal growth factor receptor 2.
jTNM: tumor, lymph node, and metastasis.
kA total of 105 patients had missing data of tumor, lymph node, and metastasis stage.